Phaseline

Companies › Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FDA018-ADC
Antibody-drug conjugate
–Phase 3Triple Negative Breast Cancer; Advanced/ Metastatic Solid TumorsJun 2027
Hemoporfin
Photodynamic therapy agent
–Phase 2Port-wine BirthmarksJan 2027
FZ-AD004
Antibody-drug conjugate
–Phase 1Advanced and Metastatic Solid TumorDec 2026
FZ-AD005–Phase 1Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05914545FZ-AD004Phase 1Advanced and Metastatic Solid TumorOncologyDec 2026
NCT05171894HemoporfinPhase 2Port-wine BirthmarksOtherJan 2027
NCT06519370FDA018-ADCPhase 3Triple Negative Breast CancerOncologyJun 2027
NCT06424665FZ-AD005Phase 1Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)OncologyDec 2027
NCT05174637FDA018-ADCPhase 1Advanced/ Metastatic Solid TumorsOncologyDec 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CStone Pharmaceuticals BioRay Pharmaceutical HUYABIO International Stemline Therapeutics Jiangsu Alphamab Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.